Professor Paul Maruff, Chief Scientific Officer
Professor Paul Maruff is one of the founders of CogState. He is a neuropsychologist with expertise in the identification and measurement of subtle behavioral and cognitive dysfunction.
Paul's research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods to identify subtle neurocognitive impairment, and to assess the efficacy of pharmacological treatment, in Alzheimer's disease, mild cognitive impairment and the HIV dementia complex. He has also used this approach to identify neurocognitive dysfunction, and monitor treatment efficacy in psychiatric diseases such as schizophrenia, obsessive-compulsive disorder and depression in adults, and attention deficit disorder, developmental dyspraxia and substance abuse in children.
Paul has published over 100 research articles in international peer-reviewed scientific journals, and has co-authored 10 book chapters and review articles.
Judith Jaeger, PhD, Senior Scientist and VP Clinical Trials
Judith Jaeger, PhD recently joined CogState as Senior Scientist and VP for Clinical Trials. Prof. Jaeger is Clinical Professor of Psychiatry and Behavioral Science at Albert Einstein College of Medicine in New York and Adjunct Professor in the CUNY Doctoral program in Neuropsychology. She brings over 25 years’ experience in clinical and experimental neuropsychology and psychopathology working at NYU school of Medicine, the Nathan Kline Institute for Psychiatric Research and at North Shore LIJ. Her research was funded by numerous foundation and NIMH grants and reported in over 50 peer-reviewed publications, an edited journal special edition and a book.
In 2006, Prof. Jaeger joined AstraZeneca where she worked globally on all phases (Ib through IV) of drug development in Alzheimer’s disease, schizophrenia, bipolar disorder and depression. She also served as a company-wide consultant on cognition measurement for CNS safety outcome measurement across all therapy areas. She represented AstraZeneca in regulatory interactions with the FDA and PMDA (Japan) and also in a wide range of consortium activities, including MATRICS-CT, where she was elected industry partner co-chair during the development of a new co-primary measure.
Prof. Jaeger also served IMI-NewMeds as EFPIA partner chair for the work package on cognition in schizophrenia, as well as a member of the work package on clinical trials design. In addition to extensive clinical, scientific and pharmaceutical development experience, Prof. Jaeger brings to CogState a passion for innovation through collaborations with colleagues in academia, industry and government, with the goal of bringing effective and safe treatments to patients who need them.
Assoc. Professor David Darby, Consultant
Associate Professor David Darby MBBS, PhD, FRACP is a founder of CogState. He graduated in Medicine at the University of Melbourne in 1981, completing a PhD in neurology and neuropsychology in 1990 and his neurology training in 1991. He served as an instructor in Behavioral Neurology at Beth Israel Hospital, Harvard Medical School from 1992 to 1995. He was Chairman of the Memory Disorders Service at the Repatriation Campus of the Austin & Repatriation Medical Centre from 1997 to 2000.
David has published over 40 research papers in international peer-reviewed scientific journals and has co-authored a neuropsychological textbook. He is a Director of the Behavioral Neurology Laboratory at the Mental Health Research Institute of Victoria.
Peter Snyder, PhD, Consultant
Professor Peter Snyder, PhD, received his doctorate in clinical psychology and behavioral neuroscience, from Michigan State University in 1992. He received a fellowship in 1992 from the Epilepsy Foundation of America, and has served as an NIMH Clinical Neurosciences Fellow and as an NIH visiting scientist. Until late 2005, as a Director and Early Clinical Leader at Pfizer Global Research & Development - Groton Laboratories, Peter led the early clinical development of novel compounds for the treatment of schizophrenia and Alzheimer's disease for Pfizer Inc.
After seven years at Pfizer, Peter left for his current post as a tenured Professor in the Department of Psychology (Neuropsychology & Cognitive Neuroscience) at the University of Connecticut. He acts as a consultant for CogState. Peter is a Fellow of the American Psychological Association, is Associate Editor of Brain and Cognition, has published over 120 peer-reviewed articles, has delivered over 100 presentations at international scientific conferences, and is the Senior Editor of a best-selling handbook on clinical neuropsychological practice.
Amy E. Veroff, PhD, Consultant
Amy E. Veroff, PhD is a neuropsychologist licensed in Massachusetts, Maryland, and California and has had more than 30 years of experience in clinical and research settings. Dr. Veroff’s clinical training and dissertation work was done at the Aphasia Research Center of Boston University. She has held a clinical appointment in the Neurology Department of Boston University Medical School and an academic appointment in the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University Medical School, providing clinical service and teaching, and was active in research studying dementia and other neuropsychiatric disorders. At Johns Hopkins, Dr. Veroff was principal investigator of a grant to study the dementia syndromes of Huntington’s and Alzheimer’s diseases.
Dr. Veroff has worked in clinical drug trials and has provided specialized scales services for nearly 25 years including establishing and leading a global division of a CRO. Under Dr. Veroff’s leadership, the group provided rater training programs and materials, central monitoring/quality assurance of study data, translation, harmonization, and cultural adaptation of scales, and other related scales services and technology for more than 200 clinical trials, training more than 20,000 thousand raters. Dr. Veroff serves on the Alzheimer’s Disease Cooperative Study (ADCS) Workgroup tasked with updating the ADAS-Cog.
Dr. Veroff is widely published, including regarding the Computerized Neuropsychological Test Battery (CNTB), a tool that she designed and co-pioneered for the assessment of CNS-drug effects. She has co-authored a book on Alzheimer’s disease clinical trials, Alzheimer’s Disease: Optimizing Drug Development Strategies.
